mometasone-furoate and Dermatitis--Atopic

Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Aged; Animals; Atrophy; Child; Child, Preschool; Clinical Trials as Topic; Controlled Clinical Trials as Topic; Cytokines; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatitis, Irritant; Double-Blind Method; Drug Eruptions; Drug Evaluation, Preclinical; Eczema; Female; Guinea Pigs; Humans; Infant; Langerhans Cells; Male; Mice; Middle Aged; Mometasone Furoate; Multicenter Studies as Topic; Pituitary-Adrenal System; Pregnadienediols; Product Surveillance, Postmarketing; Randomized Controlled Trials as Topic; Rats; Skin

Topical glucocorticoids are still among the dermatologicals most frequently used. This is due to their undebatable potency in inflammatory skin disease. Their use is limited by the fear of side effects both systemic and topical, especially skin atrophy. Hence, congeners with an increased benefit-risk ratio are urgently needed and research on new drugs no longer focuses on more active drugs but safer ones. Only recently, evidence has been forwarded that the goal is realistic. Some new glucocorticoids, especially the nonfluorinated double-ester type such as prednicarbate, appear promising. In fact, they seem to affect fibroblast growth in vitro as well as skin thickness in vivo less than equipotent conventional glucocorticoids. Pertinent findings in humans have been obtained with the use of ultrasound equipment. The relevant aspects of chemistry, pharmacology, clinical benefits, and toxicology of the various glucocorticoids old and new are reviewed, as are potential future alternatives.

Topics: Administration, Topical; Anti-Inflammatory Agents; Atrophy; Betamethasone Valerate; Dermatitis, Atopic; Glucocorticoids; Humans; Mometasone Furoate; Odds Ratio; Prednisolone; Pregnadienediols; Psoriasis; Skin

Atopic dermatitis (AD), chronic eczema, and pruritus hiemalis are a set of prevalent chronic xerotic skin disorders that share clinical features such as dryness, scales, and pruritus. A ceramide deficiency and defective epidermal functions are common in these diseases. This study was designed to assess the effect of ceramide-linoleic acid (LA-Cer)-containing moisturizer as an adjunctive therapy in the treatment of AD, chronic eczema, and pruritus hiemalis. In a 2-month study, patients with one of these three diseases were divided into two groups. The control group was treated with mometasone furoate (0.1%) cream (MF), whereas the treatment group received 0.1% MF in combination with an LA-Cer-containing moisturizer. Capacitance and transepidermal water loss were measured in normal and lesional skin, along with Eczema Assessment Severity Index and pruritus scores at Weeks 0, 2, 4, and 8. The results showed that tropical applications of an LA-Cer-containing moisturizer in combination with a topical glucocorticoid accelerated the reestablishment of epidermal permeability barrier and the amelioration of pruritus in patients with AD and pruritus hiemalis. However, it did not provide the same effect for chronic eczema. Thus, the efficacy of this combination therapy for this set of xerotic disorders requires further evaluation.

Topics: Administration, Cutaneous; Ceramides; Dermatitis, Atopic; Dermatologic Agents; Eczema; Electric Capacitance; Emollients; Glucocorticoids; Humans; Linoleic Acid; Mometasone Furoate; Pruritus; Severity of Illness Index; Treatment Outcome; Water Loss, Insensible

Scratching and itch are common clinical signs of atopic dermatitis (AD). Studies of adult patients have shown that a decrease in scratching behaviour results in regression of inflammation and improved healing of the skin.. To investigate whether a modified habit reversal (HR) treatment protocol could be used for the treatment of scratching in children to improve skin status.. The study is a single-blind, randomized controlled trial of 39 patients who started with registration a week before randomization into one of two groups (intervention or control). The participants in the intervention group received a habit-breaking therapy of their scratching behaviour (i.e. HR) in addition to a potent steroid (mometasone furoate), whereas the patients in the control group received the steroid alone. The patients were assessed by an independent dermatologist after the first week of registration (baseline assessment) and then after 3 and 8 weeks of treatment. The primary efficacy variable was a change in objective Scoring Atopic Dermatitis (SCORAD).. At the end of the 3-week treatment period, the change in mean objective SCORAD was significantly (P = 0·027) higher in the intervention group (-31·9 ± 9·5) than in the control group (-23·8 ± 10·1). After the 8-week follow-up, the change in mean objective SCORAD was significantly (P = 0·0038) higher in the intervention group (-31·7 ± 10·4) than in the control group (-19·7 ± 9·4).. The treatment of scratching with the HR method in combination with a potent steroid was found to improve skin status significantly after 3 and 11 weeks.

Topics: Administration, Cutaneous; Antipruritics; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; Dermatitis, Atopic; Female; Habits; Humans; Male; Mometasone Furoate; Ointments; Pruritus; Single-Blind Method; Treatment Outcome

Wet-wrap treatment (WWT) has been advocated as a relatively effective treatment in children with severe atopic dermatitis (AD). WWT often serves as crisis intervention for AD.. We sought to evaluate the use of WWT with diluted corticosteroids in comparison with emollient in children with severe AD during 4 weeks in a proactive schedule during which the frequency of corticosteroid applications was tapered.. A randomized, double-blind, placebo-controlled study was performed in children aged 6 months to 10 years with severe AD (objective SCORAD at least 40 ± 5), comparing WWT with diluted corticosteroids (1:3 mometasone furoate 0.1% ointment and for the face 1:19 mometasone furoate 0.1% ointment under a mask) with emollient (petrolatum 20% in cetomacrogol cream). The primary outcome was improvement of the objective SCORAD; secondary outcomes included Patient-Oriented Eczema Measure and quality-of-life index.. WWT with diluted corticosteroids acted faster and was more efficacious than WWT with emollients. Best results were obtained in age groups 6 to 9 years and 0 to 3 years. The difference in efficacy evaluated by objective SCORAD was significant at all measuring points. This also applied to the quality-of-life index.. The study group was relatively small.. WWT for severe AD is an effective therapy option for at least a period of 4 weeks.

Topics: Administration, Topical; Adrenal Cortex Hormones; Bandages; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Emollients; Female; Follow-Up Studies; Humans; Infant; Male; Mometasone Furoate; Petrolatum; Pregnadienediols; Prospective Studies; Reference Values; Risk Assessment; Treatment Outcome

The skin barrier plays a crucial role in the pathophysiology of atopic dermatitis. The quality of the skin barrier can be assessed using a new semi-quantitative method to measure intercellular lipid lamellae. This procedure was used to evaluate the influence of the topical application of the calcineurin inhibitor tacrolimus 0.1% ointment (Protopic®) versus mometasone furoate cream (Ecural®) on the quality of the skin barrier.. 20 adult patients with active atopic dermatitis (SCORAD 10-63) were included in an open, non-interventional study. Lesions on their forearms were treated twice daily over 10 days with either tacrolimus 0.1% ointment or mometasone furoate cream. At the beginning and the end of the treatment period, SCORAD, TEWL and skin hydration were determined and the intercellular lipids were measured using transmission electron microscopy.. The SCORAD improved in both groups nearly to the same extent, whereas TEWL and skin hydration improved significantly only in the tacrolimus group. Using the semi-quantitative analysis of intercellular lipid length per 1,000 nm(2) intercellular space, a twofold increase for mometasone furoate cream and a fourfold increase for tacrolimus 0.1% ointment were determined.. In addition to its known antiinflammatory effect, tacrolimus 0.1% ointment leads also to a measurable increase of the lipids of the skin barrier in patients with atopic dermatitis, exceeding the effect of mometasone furoate cream.

Topics: Administration, Topical; Adult; Anti-Allergic Agents; Anti-Inflammatory Agents; Dermatitis, Atopic; Epidermis; Female; Humans; Immunosuppressive Agents; Male; Middle Aged; Mometasone Furoate; Ointments; Pregnadienediols; Skin Absorption; Skin Cream; Tacrolimus; Treatment Outcome

 Lipoxins are potential anti-inflammatory mediators and serve as an endogenous 'braking signal' in the inflammatory process. Accumulating evidence has indicated the efficacy of lipoxin A(4) (LXA(4) ) and its analogs in the treatment of many animal models of inflammatory diseases..  This study investigates the efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in the topical treatment of infantile eczema.. In this two-centre, double-blind, placebo-controlled, randomized, parallel-groups comparative study, 60 patients were randomly assigned to receive either the 15(R/S)-methyl-lipoxin A(4) cream, mometasone furoate (Eloson, Schering-Plough, Shanghai, China) or placebo for 10days. The efficacy was determined using the Severity Scale Score (SSS), Eczema Area and Severity Index (EASI) and the Infants' Dermatitis Quality of Life Index (IDQOL). Safety was monitored by physical examination, laboratory investigation and documentation of clinical adverse events..  The treatment of eczema with 15(R/S)-methyl-LXA(4) cream significantly relieved the severity, induced a recovery, and improved the quality of life of the patients, as demonstrated by significantly reduced SSS, EASI and IDQOL, respectively, in a way similar to the efficacy of Eloson. All safety parameters remained within normal limits. No clinical adverse event was found in the three patient groups..  15(R/S)-methyl-LXA(4) was well tolerated, and significantly reduced the severity of eczema. The results of this small exploratory study suggest that 15(R/S)-methyl-LXA(4) warrants further investigation in the treatment of eczema.

Topics: Administration, Cutaneous; Anti-Allergic Agents; Anti-Inflammatory Agents; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Infant; Lipoxins; Male; Mometasone Furoate; Ointments; Pregnadienediols; Quality of Life; Severity of Illness Index; Treatment Outcome

This double-blind controlled phase II study was conducted to compare a newly developed formulation of mometasone furoate with a water content of 33% (Monovo® Cream) and with a smooth consistency versus the commercially available fatty cream of mometasone furoate (Ecural® Fettcreme) in terms of efficacy, cosmetic properties, and patients' acceptance. In 20 patients with mild to moderate atopic eczema, the preparations were tested intraindividually in a randomized mode and in two comparable lesion areas. Both preparations were equally effective and well tolerated. Due to improved cosmetic properties, the new formulation was preferred by the patients when asked for preferential use. Quality of life could be improved by treating with both preparations.

Topics: Administration, Topical; Adolescent; Dermatitis, Atopic; Double-Blind Method; Female; Humans; Male; Mometasone Furoate; Pregnadienediols; Quality of Life; Self Report; Skin Cream; Treatment Outcome

Atopic dermatitis is a common skin disease in Thai children. The treatment of atopic dermatitis requires topical corticosteroids, emollients, systemic antihistamine as well as avoidance of the precipitating factors. A double blind multicenter placebo controlled study was conducted to assess the therapeutic efficacy of topical mometasone furoate 0.1 per cent cream in combination with loratadine syrup. Forty-eight patients, 23 boys and 25 girls, mean age 73.67 months, with atopic dermatitis were included in the study. The severity of the disease was measured by using the SCORAD index including the degree of erythema, dryness, edema/papulation, oozing/crusting, lichenification, and excoriation. Total area involved was measured and a target area of dermatitis was selected for specific evaluation. The degree of clinical signs and pruritic symptom was graded. The sensation of pruritus, disturbance of sleep due to pruritus, and feeling of sleepiness in the morning were recorded. Mometasone furoate 0.1 per cent cream was applied to all patients once daily. One group received loratadine syrup and another group received placebo syrup. They were followed-up on day 5, 8 and 15. The severity of atopic dermatitis and pruritus significantly decreased after 14 days of treatment in both groups (p < 0.001). There was no difference in therapeutic response between the loratadine and placebo groups (p = 0.99). All signs examined had decreased by the end of the study. The result demonstrated that 0.1 per cent mometasone therapy is very effective for treating childhood atopic dermatitis. Loratadine did not show beneficial effect when combined with good topical corticosteroid but it was safe and had no serious side effect on the children.

Topics: Administration, Cutaneous; Antipruritics; Child; Child, Preschool; Dermatitis, Atopic; Dosage Forms; Double-Blind Method; Drug Therapy, Combination; Female; Glucocorticoids; Humans; Loratadine; Male; Mometasone Furoate; Pregnadienediols

The wet-wrap dressing technique has proved to be beneficial in cases of exacerbated atopic dermatitis (AD) skin lesions.. The effect of wet-wrap dressings was investigated in a controlled trial comparing a steroid (mometasone furoate 0.1%)-containing and a steroid-free (vehicle) preparation in an in-patient comparison study.. 20 children aged 2-17 years with exacerbated AD were treated twice daily with wet-wrap dressings over a 5-day period.. AD in treated areas significantly improved in both study arms; however, the effect was significantly better in the mometasone-treated group (p < 0.01). Transepidermal water loss improved in both arms without any significant differences. Staphylococcus aureus colonization decreased during the first 3 days of active treatment independently of the therapeutic modalities chosen. At day 5, colony counts further dropped on the steroid-treated lesions.. Application of the wet-wrap dressing technique for exacerbated AD lesions is effective, combination with a topical steroid being superior to a steroid-free application without bearing the risk of a bacterial superinfection.

Topics: Administration, Topical; Adolescent; Anti-Inflammatory Agents; Bandages; Child; Child, Preschool; Combined Modality Therapy; Dermatitis, Atopic; Double-Blind Method; Female; Follow-Up Studies; Glucocorticoids; Humans; Male; Mometasone Furoate; Pregnadienediols; Reference Values; Severity of Illness Index; Skin Absorption; Treatment Outcome

Atopic dermatitis is a severe chronic skin disease often deteriorated by the presence of microorganisms and often responds well to treatment with potent corticosteroids. However, the long-term use of potent topical corticosteroids are accompanied by side-effects such as skin atrophy.. To study the effect and safety of prophylactic treatment with mometasone furoate fatty cream (contains hexylene glycol) for 6 months in patients with atopic dermatitis.. Sixty-one of 68 (90%) patients were still free of their disease after 6 months of twice weekly treatment and only one showed possible treatment related signs of skin atrophy. The number of Staphylococcus aureus and Pityrosporum ovale were significantly reduced in cleared patients.. Mometasone furoate fatty cream is effective and safe both for treatment and as a prophylaxis in patients with atopic dermatitis.

Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Dermatitis, Atopic; Drug Administration Schedule; Female; Glucocorticoids; Humans; Male; Mometasone Furoate; Pregnadienediols; Safety; Time Factors

Chronic hand eczema can be incapacitating, and there is little knowledge of the efficacy and safety of long-term treatment with topical corticosteroids. We compared the efficacy and safety of two different schedules for the treatment of chronic hand eczema with a potent topical corticosteroid, mometasone furoate. In a prospective, open, randomized trial, 120 patients with chronic hand eczema were treated daily with mometasone furoate fatty cream until the dermatitis cleared or for a maximum of 9 weeks. Those who cleared were randomized to treatment for up to 36 weeks with mometasone furoate on Sunday, Tuesday and Thursday (group A), mometasone furoate on Saturday and Sunday (group B) or no further corticosteroid treatment (group C). In the event of relapse, patients were permitted daily treatment with mometasone furoate for 3 weeks on two separate occasions. For 50 of 106 randomized patients, daily treatment for 3 weeks controlled their dermatitis; 29 needed 6 weeks and 27 needed 9 weeks of treatment. During the maintenance phase, 29 of 35 (83%) in group A, 25 of 37 (68%) in group B and nine of 34 (26%) in group C had no recurrences (P = 0.001, chi2-test). Side-effects were minimal. It is concluded that long-term, intermittent treatment of chronic hand eczema with mometasone furoate fatty cream is effective and safe.

Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Dermatitis, Allergic Contact; Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Irritant; Dermatitis, Occupational; Drug Administration Schedule; Eczema; Hand Dermatoses; Humans; Middle Aged; Mometasone Furoate; Pregnadienediols; Recurrence; Survival Analysis; Time Factors

Topics: Administration, Topical; Anti-Inflammatory Agents; Child; Child, Preschool; Dermatitis, Atopic; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Resistance; Female; Follow-Up Studies; Humans; Hydrocortisone; Male; Mometasone Furoate; Pregnadienediols; Treatment Outcome

We conducted a 6-week randomized, blinded study that compared mometasone furoate 0.1% cream, applied once daily, and hydrocortisone 1.0% cream, applied twice daily, in 48 children with moderate to severe atopic dermatitis. Mometasone furoate, a moderate-potency steroid, produced significantly greater improvement than the low-potency hydrocortisone used twice daily. The difference in therapeutic response was particularly evident in patients with involvement of more than 25% of their body surface area. Morning plasma cortisol levels were assayed before treatment, after 1 week of therapy, and at the end of the clinical trial. Plasma cortisol levels were transiently suppressed in one child who was treated with hydrocortisone and in none of the children treated with mometasone.

Topics: Administration, Topical; Anti-Inflammatory Agents; Child; Child, Preschool; Dermatitis, Atopic; Double-Blind Method; Humans; Hydrocortisone; Infant; Mometasone Furoate; Ointments; Pregnadienediols

Topics: Administration, Topical; Cyclic Nucleotide Phosphodiesterases, Type 4; Dermatitis, Atopic; Emollients; Gene Expression; Humans; Mometasone Furoate; Treatment Outcome

This retrospective study investigated the effectiveness of calamine lotion (CL) as an adjunctive therapy to mometasone furoate ointment (MFO) in the treatment of infant eczema (IE). This retrospective study analyzed the electronic medical records of 50 IE infants. They were allocated to a treatment group or a control group, with 25 subjects in each group. All infants in both groups received MFO. In addition, infants in the treatment group underwent CL. The outcomes were effectiveness based on the eczema area and severity index, lesion area, and pruritus severity. We analyzed the outcomes before and after treatment. The results of this study showed that infants in the treatment group had more effective in effectiveness based on eczema area and severity index (P < .01), lesion area (P < .01), and pruritus severity (P = .01) than those in the control group. However, no medical records reported any adverse events in either group. The results of this study showed that CL added to MFO was more effective than MFO alone in the treatment of infants with IE.

Topics: Dermatitis, Atopic; Eczema; Humans; Mometasone Furoate; Ointments; Pruritus; Retrospective Studies

The epidermal skin barrier and lipids that are integral to its structure are impaired in atopic dermatitis (AD). Current treatment guidelines include proactive therapy.. This study assessed the effect of 12 weeks of proactive treatment with tacrolimus ointment 0.1% (TAC) compared with mometasone furoate cream (MF) on specific skin barrier lipids in patients with AD who previously received 10 days of reactive treatment with either agent.. This was an open-label, non-interventional study. In the reactive phase, forearm lesions in 20 patients were treated with either TAC or MF twice daily for 10 days. In the subsequent proactive phase, patients applied TAC or MF twice weekly for 12 weeks (. Over the 12-week proactive treatment period, the mean local SCORAD significantly decreased in the TAC and MF treatment group. Levels of total and individual ceramides increased in both groups. Normalized intercellular lipid lamellae values were significantly higher with proactive TAC treatment than MF and undistinguishable from healthy skin.. The results show that proactive treatment with TAC is superior in restoring the skin barrier.

Topics: Ceramides; Dermatitis, Atopic; Humans; Immunosuppressive Agents; Mometasone Furoate; Ointments; Tacrolimus; Treatment Outcome

Topics: Administration, Topical; Adrenal Cortex Hormones; Anti-Allergic Agents; Dermatitis, Atopic; Eczema; Humans; Mometasone Furoate

Atopic dermatitis (AD) affects up to 20% of the pediatric population, with a growing prevalence over the past 30 years. Topical corticosteroids (TCS) are commonly used as a first-line topical therapy for AD and are prescribed in 59% of all AD visits. However, some topical corticosteroids are prescribed outside of their age range indications. This paper aims to explore the frequency with which topical corticosteroids are prescribed for AD outside of their FDA-approved age range.. Data on prescribing patterns for AD were obtained from the National Ambulatory Medical Care Survey (NAMCS). We assessed the frequency of off-label use of topical corticosteroids with respect to age indications in four specific age-groups, as delineated in the data (0-1, 2-7, 8-18, and 19+ years).. All prescribed topical corticosteroids found in the NAMCS database have an indication for AD or other inflammatory dermatoses or pruritic dermatoses. However, some medications were prescribed outside of their FDA-approved age indications. These off-label prescription rates ranged from 52% for desoximetasone to 0% for halobetasol and alclometasone, or rates lower than could be detected by our study.. Much like other medications for AD treatment, TCS are sometimes used off-label. The off-label use of topical corticosteroids to treat pediatric AD highlights a gap between clinical practice and regulating guidelines. Additional pediatric studies would offer a greater body of evidence to maintain or expand label indications for the use of TCS in younger patients.

Topics: Child; Dermatitis, Atopic; Dermatologic Agents; Health Care Surveys; Humans; Infant; Infant, Newborn; Mometasone Furoate; Off-Label Use; Practice Patterns, Physicians'

Atopic keratoconjunctivitis (AKC) remains a difficult diagnosis despite advances in imaging technologies. This is a case study of the diagnostic and treatment course for a patient with AKC.. A 15-year-old male complained of progressively increasing pain, redness, watering and blurred vision in the right eye. The medical history showed that the patient suffered from itching on the hands, knees, neck and the eye skin one year before the onset of initial symptoms in the affected eye.. A final diagnosis of stage III AKC with atopic dermatitis (AD) was reached.. The patient was used 0.1% tacrolimus eye drops and 0.3% gatifloxacin eye gel after antimicrobial susceptibility test was performed. In the presence of AD, 0.1% mometasone furoate cream and 0.03% tacrolimus ointment were applied twice daily.. One month after starting treatment, the conjunctivitis and corneal ulcer rapidly improved along with reduced lid papillae. Macular grade corneal opacity was noticed with minimal thinning. The AD also rapidly improved. At the end of two months patient was asymptomatic with a significant improvement in his quality of life.. Proper diagnosis of AKC especially when associated with dermatological signs along with management of AD in conjunction with dermatologist is necessary to prevent corneal involvement which can cause permanent visual disability is of utmost importance. We also noticed that topical tacrolimus is a good option for the treatment of severe AKC with AD along with systemic immunosupressants.

Topics: Administration, Topical; Adolescent; Anti-Allergic Agents; Anti-Bacterial Agents; Conjunctivitis, Allergic; Corneal Ulcer; Dermatitis, Atopic; Fluoroquinolones; Gatifloxacin; Humans; Immunosuppressive Agents; Male; Mometasone Furoate; Ophthalmic Solutions; Tacrolimus; Treatment Outcome

Topical ear medications, often containing a glucocorticoid, are used to treat the clinical signs of atopic otitis in dogs. Studies have looked at the inhibitory effect of topical glucocorticoids on intradermal testing (IDT), but only one previously published study evaluated the influence of an otic glucocorticoid on the results of IDT in dogs.. To assess what influence the absorption of the diester glucocorticoid mometasone furoate (MF) had on intradermal test immediate reactions, to determine an appropriate withdrawal time prior to IDT.. Twenty atopic dogs were enrolled. On day 0, histamine, rabbit anticanine IgE antiserum and saline were injected intradermally. After 20 min, a global wheal score (GWS) was determined. The otic medication, MF, was applied once daily for 14 days. Intradermal injections were then repeated and, if the GWS was within 25% of pretreatment values, the study was completed for this dog. If the GWS had decreased by ≥25% from the baseline value, the otic medication was withdrawn, and the GWS was repeated every 7 days until its value was within 25% of the original GWS.. Three of the 20 dogs completed the study on day 14, while 17 of 20 dogs ended it on day 21, 7 days after withdrawal of the drug, MF.. Results from this study show that a withdrawal period of ≤7 days is possible before performing IDT in atopic dogs with active otitis externa treated with ≤14 days of MF.

Topics: Administration, Topical; Alanine Transaminase; Alkaline Phosphatase; Animals; Anti-Inflammatory Agents; Dermatitis, Atopic; Dog Diseases; Dogs; Ear, External; Female; Intradermal Tests; Male; Mometasone Furoate; Otitis Externa; Pregnadienediols

Topics: Anti-Allergic Agents; Cyclohexylamines; Dermatitis, Atopic; Dermatitis, Occupational; Epoxy Resins; Humans; Loratadine; Male; Middle Aged; Mometasone Furoate; Pregnadienediols

Atopic dermatitis (AD) is aggravated by mechanical irritation and bacterial colonization.. This study compared the efficacy of an antimicrobial silk fabric (DermaSilk) with that of a topical corticosteroid in the treatment of AD.. Fifteen children were enrolled and wore a dress, where the left side was made of DermaSilk and the right side was made of cotton. The right arm and leg were treated daily with the corticosteroid mometasone for 7 days. The treatment efficacy was measured with a modified EASI (Eczema Area and Severity Index) and with an assessment by the patients/parents and by a physician. All patients were evaluated at baseline, as well as 7 and 21 days after the initial examination.. All parameters showed that, irrespective of the treatment, there was a significant decrease of eczema after 7 days. No significant difference between DermaSilk-treated and corticosteroid-treated skin could be observed.. DermaSilk showed potential to become an effective treatment of AD.

Topics: Administration, Cutaneous; Anti-Allergic Agents; Anti-Bacterial Agents; Child; Child, Preschool; Clothing; Colony Count, Microbial; Dermatitis, Atopic; Eczema; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Mometasone Furoate; Pregnadienediols; Silk; Staphylococcal Skin Infections; Staphylococcus aureus; Treatment Outcome

Staphylococcus aureus has important implications for the pathogenesis of atopic dermatitis (AD). In some patients S. aureus can be eradicated from the skin during anti-inflammatory treatment, while in others bacterial colonization is persistent. Potential mechanisms and features of these two distinct groups of patients are not known.. Accordingly, we studied relationships between the ability to eliminate S. aureus during an anti-inflammatory treatment and selected clinical and immunological features.. Quantitative assessment of S. aureus on the skin, in nasal vestibule and throat, serum IgE levels, CD4/CD8 T-cell ratio, lymphocyte proliferation and phagocyte oxidative burst were determined during the exacerbation and after 4 and 12 weeks of the treatment using topical steroid and oral antihistamine in 34 patients with AD.. S. aureus was found on the skin of all 34 patients during exacerbation. Disease severity scoring of atopic dermatitis (SCORAD) correlated with the density of bacteria. Treatment with oral antihistamine and topical steroid resulted in a significant alleviation of symptoms, which correlated with the elimination of S. aureus from the skin in 70% of patients. In the remaining 30% of patients, dense (more than 10(10)/cm2) S. aureus skin colonization, persisted despite the treatment. Patients with persistent S. aureus presented with higher serum IgE levels, lower lymphocyte proliferation in response to staphylococcal enterotoxin B, phytohaemagluttinin and anti-CD3. Persistence of S. aureus was more common in men.. Patients with AD differ in the ability to clear S. aureus from the skin during anti-inflammatory treatment, which appears to be related to the abnormalities in immunological parameters. Local antibiotic therapy should be considered only in patients with persistent S. aureus colonization.

Topics: Administration, Topical; Adult; Anti-Allergic Agents; CD4-CD8 Ratio; Cetirizine; Dermatitis, Atopic; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Immunoglobulin E; Male; Mometasone Furoate; Nose; Pharynx; Pregnadienediols; Skin; Staphylococcal Skin Infections; Staphylococcus aureus

Topics: Administration, Topical; Anti-Inflammatory Agents; Betamethasone; Dermatitis, Atopic; Glucocorticoids; Humans; Mometasone Furoate; Pregnadienediols; Steroids, Fluorinated

Topics: Administration, Cutaneous; Anti-Inflammatory Agents; Dermatitis, Atopic; Facial Dermatoses; Follow-Up Studies; Glucocorticoids; Humans; Intertrigo; Mometasone Furoate; Ointments; Pregnadienediols; Psoriasis; Safety; Time Factors